Connective and Soft Tissue Neoplasm

cancer family

Identifier: CI-CAN-00000010
Entity page: /cancer/connective-and-soft-tissue-neoplasm ↗
Edges: 2,274

Neighbours: 15 genes20 drugs10 trials
Drawn: 45 of 45 neighbours (cap 60); table lists every fetched edge

Accepted: cancer:<slug>, gene:<symbol>, variant:<slug>, drug:<slug>, trial:<NCT id>, or a bare CI id. Find slugs with search.

Most connectedLung Non-Small Cell Carcinoma 3,149 Malignant Colorectal Neoplasm 1,866 ABL1 298 EGFR 276 Imatinib 450 Dasatinib 321

Neighbourhood

Radial view

Focus at the centre; neighbours grouped by entity type. Click a node to re-centre the graph on it; ↗ opens the entity page. Hover a spoke for relationship, evidence level, cancer context and source.

Edges

Every edge, grouped by relationship

Source-native edges first (aggregated per neighbour, direction, evidence level and source), then derived registry links. Up to 15 per relationship (10 trials); “show all” raises one group to 200.

Relationship	Neighbour	Direction	Evidence level	Cancer context	Support	Claim	Source	Expand
Connective and Soft Tissue Neoplasm approved for …APPROVED_FORderived6 of 6
← approved for	Leuprolideother FDA (US) · approved · 2020-05-01 · FENSOLVI ® is indicated for the treatment of pediatric patients 2 years of age and older with central precocious puberty (CPP). FENSOLVI is…	—	approved	Conventional Osteosarcoma	1	Regulatory	openfda	graph →
← approved for	Triptorelin

Paths

Strongest chains

Gene → variant → drug chains anchored in this cancer (or a descendant), ranked by source-native evidence level then support, with the approval and trial registry hops when they exist.

ALK Fusion Crizotinib1 active / 3 trials
Curatedlevel Asensitivity· support 4civicObservedcohort frequency not yet available for ALK in this cancerno approval record in this cancercontext: Inflammatory Myofibroblastic Tumor, Vaginal Sarcoma
KIT Exon 11 Mutation Imatinib10 active / 30 trials
Curatedlevel Asensitivity· support 2civicObservedKIT altered in 77% (384 / 499 cases, largest of 3 cohorts)no approval record in this cancercontext: Gastrointestinal Stromal Tumor
KIT Exon 9 Mutation Imatinib10 active / 30 trials
Curatedlevel Asensitivity· support 2civicObservedKIT altered in 77% (384 / 499 cases, largest of 3 cohorts)no approval record in this cancercontext: Gastrointestinal Stromal Tumor
KIT Exon 11 Mutation Regorafenib Anhydrous0 active / 0 trials
Curatedlevel Bsensitivity· support 3civicObservedKIT altered in 77% (384 / 499 cases, largest of 3 cohorts)no approval record in this cancercontext: Gastrointestinal Stromal Tumor
KIT Exon 9 Mutation Sunitinib5 active / 24 trials
Curatedlevel Bsensitivity· support 2civicObservedKIT altered in 77% (384 / 499 cases, largest of 3 cohorts)no approval record in this cancercontext: Gastrointestinal Stromal Tumor
CDK4 Amplification Palbociclib5 active / 11 trials
Curatedlevel Bsensitivity· support 2civicObservedcohort frequency not yet available for CDK4 in this cancerno approval record in this cancercontext: Liposarcoma
KIT Exon 9 Mutation Regorafenib Anhydrous0 active / 0 trials
Curatedlevel Bsensitivity· support 1civicObservedKIT altered in 77% (384 / 499 cases, largest of 3 cohorts)no approval record in this cancercontext: Gastrointestinal Stromal Tumor
KIT EXPRESSION Imatinib10 active / 30 trials
Curatedlevel Bsensitivity· support 1civicObservedKIT altered in 77% (384 / 499 cases, largest of 3 cohorts)no approval record in this cancercontext: Gastrointestinal Stromal Tumor

Each hop keeps its own claim category: cohort alteration frequency (observed, cases ≥ 20), CIViC predictive edge (curated, level as stated by CIViC), regulatory approval (authority, jurisdiction, date as published), trial count (registry). A missing hop is shown as missing — never filled in. Not treatment guidance.

Connective and Soft Tissue Neoplasm altered in cohorts of …ALTERED_INderived15 of 101show all (up to 200)
← altered in cohorts of	KIT 384 / 499 cases (77 %) · ssm · gist_msk_2022 · largest of 3 cohorts	—	—	Gastrointestinal Stromal Tumor	3	Observed	cbioportal	graph →
← altered in cohorts of	TP53 167 / 261 cases (64 %) · ssm · TCGA-SARC · largest of 4 cohorts	—	—	Sarcoma	4	Observed	gdc	graph →
← altered in cohorts of	RB1 165 / 261 cases (63 %) · ssm · TCGA-SARC	—	—	Sarcoma	1	Observed	gdc	graph →
← altered in cohorts of	ITM2B 154 / 261 cases (59 %) · ssm · TCGA-SARC	—	—	Sarcoma	1	Observed	gdc	graph →
← altered in cohorts of	LPAR6 154 / 261 cases (59 %) · ssm · TCGA-SARC	—	—	Sarcoma	1	Observed	gdc	graph →
← altered in cohorts of	RCBTB2 154 / 261 cases (59 %) · ssm · TCGA-SARC	—	—	Sarcoma	1	Observed	gdc	graph →
← altered in cohorts of	CAB39L 153 / 261 cases (59 %) · ssm · TCGA-SARC	—	—	Sarcoma	1	Observed	gdc	graph →
← altered in cohorts of	CDADC1 152 / 261 cases (58 %) · ssm · TCGA-SARC	—	—	Sarcoma	1	Observed	gdc	graph →
← altered in cohorts of	CYSLTR2 152 / 261 cases (58 %) · ssm · TCGA-SARC	—	—	Sarcoma	1	Observed	gdc	graph →
← altered in cohorts of	FNDC3A 152 / 261 cases (58 %) · ssm · TCGA-SARC	—	—	Sarcoma	1	Observed	gdc	graph →
← altered in cohorts of	MLNR 152 / 261 cases (58 %) · ssm · TCGA-SARC	—	—	Sarcoma	1	Observed	gdc	graph →
← altered in cohorts of	SETDB2 152 / 261 cases (58 %) · ssm · TCGA-SARC	—	—	Sarcoma	1	Observed	gdc	graph →
← altered in cohorts of	MED4 151 / 261 cases (58 %) · ssm · TCGA-SARC	—	—	Sarcoma	1	Observed	gdc	graph →
← altered in cohorts of	NUDT15 151 / 261 cases (58 %) · ssm · TCGA-SARC	—	—	Sarcoma	1	Observed	gdc	graph →
← altered in cohorts of	PHF11 151 / 261 cases (58 %) · ssm · TCGA-SARC	—	—	Sarcoma	1	Observed	gdc	graph →

Connective and Soft Tissue Neoplasm investigated in trials for …INVESTIGATED_IN_TRIALSderived15 of 201show all (up to 200)
→ investigated in trials for	Doxorubicinsmall molecule 96 trials (16 active) · roll-up of the cancer and its descendants	—	—	Connective and Soft Tissue Neoplasm	96	Observed	clinicaltrials	graph →
→ investigated in trials for	Ifosfamidesmall molecule 65 trials (8 active) · roll-up of the cancer and its descendants	—	—	Connective and Soft Tissue Neoplasm	65	Observed	clinicaltrials	graph →
→ investigated in trials for	Cyclophosphamidesmall molecule 57 trials (11 active) · roll-up of the cancer and its descendants	—	—	Connective and Soft Tissue Neoplasm	57	Observed	clinicaltrials	graph →
→ investigated in trials for	Filgrastimother 54 trials (3 active) · roll-up of the cancer and its descendants	—	—	Connective and Soft Tissue Neoplasm	54	Observed	clinicaltrials	graph →
→ investigated in trials for	Vincristinesmall molecule 42 trials (8 active) · roll-up of the cancer and its descendants	—	—	Connective and Soft Tissue Neoplasm	42	Observed	clinicaltrials	graph →
→ investigated in trials for	Imatinib Mesylatesmall molecule 41 trials (3 active) · roll-up of the cancer and its descendants	—	—	Connective and Soft Tissue Neoplasm	41	Observed	clinicaltrials	graph →
→ investigated in trials for	Etoposidesmall molecule 38 trials (3 active) · roll-up of the cancer and its descendants	—	—	Connective and Soft Tissue Neoplasm	38	Observed	clinicaltrials	graph →
→ investigated in trials for	Imatinibsmall molecule 30 trials (10 active) · roll-up of the cancer and its descendants	—	—	Connective and Soft Tissue Neoplasm	30	Observed	clinicaltrials	graph →
→ investigated in trials for	Pembrolizumabmonoclonal antibody 28 trials (17 active) · roll-up of the cancer and its descendants	—	—	Connective and Soft Tissue Neoplasm	28	Observed	clinicaltrials	graph →
→ investigated in trials for	Irinotecansmall molecule 27 trials (7 active) · roll-up of the cancer and its descendants	—	—	Connective and Soft Tissue Neoplasm	27	Observed	clinicaltrials	graph →
→ investigated in trials for	Cisplatinsmall molecule 26 trials (2 active) · roll-up of the cancer and its descendants	—	—	Connective and Soft Tissue Neoplasm	26	Observed	clinicaltrials	graph →
→ investigated in trials for	Gemcitabinesmall molecule 26 trials (2 active) · roll-up of the cancer and its descendants	—	—	Connective and Soft Tissue Neoplasm	26	Observed	clinicaltrials	graph →
→ investigated in trials for	Sunitinibsmall molecule 24 trials (5 active) · roll-up of the cancer and its descendants	—	—	Connective and Soft Tissue Neoplasm	24	Observed	clinicaltrials	graph →
→ investigated in trials for	Regorafenibsmall molecule 22 trials (5 active) · roll-up of the cancer and its descendants	—	—	Connective and Soft Tissue Neoplasm	22	Observed	clinicaltrials	graph →
→ investigated in trials for	Bevacizumabmonoclonal antibody 21 trials (1 active) · roll-up of the cancer and its descendants	—	—	Connective and Soft Tissue Neoplasm	21	Observed	clinicaltrials	graph →

Connective and Soft Tissue Neoplasm studied in …STUDIED_INderived10 of 1,966show all (up to 200)
→ studied in	NCT01109394recruiting Comprehensive Omics Analysis of Pediatric and Adult Solid Tumors and Establishment of a Repository for Related Biological Studies · condition mapped ONTOLOGY_EXACT · 1,966 trials mapped (518 active)	—	—	Sarcoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT02923778Phase 2 · active not recruiting Talimogene Laherparepvec and Radiation Therapy in Treating Patients With Newly Diagnosed Soft Tissue Sarcoma That Can Be Removed by Surgery · condition mapped ONTOLOGY_EXACT · 1,966 trials mapped (518 active)	—	—	Liposarcoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT03759717recruiting Molecular and Cellular Characterization of Skull Base Tumors · condition mapped ONTOLOGY_EXACT · 1,966 trials mapped (518 active)	—	—	Skull Base Neoplasm	1	Observed	clinicaltrials	graph →
→ studied in	NCT04924075Phase 2 · recruiting Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015) · condition mapped CURATED_BROADER · 1,966 trials mapped (518 active)	—	—	Gastrointestinal Stromal Tumor	1	Observed	clinicaltrials	graph →
→ studied in	NCT06441331Phase 1 · recruiting Phase I Trial to Determine the Dose and Evaluate the PK and Safety of Lutetium Lu 177 Edotreotide Therapy in Pediatric Participants With SSTR-positive Tumors · condition mapped ALIAS · 1,966 trials mapped (518 active)	—	—	Gastrointestinal Stromal Tumor	1	Observed	clinicaltrials	graph →
→ studied in	NCT07124000recruiting DESTINY-PANTUMOUR04 · condition mapped ONTOLOGY_EXACT · 1,966 trials mapped (518 active)	—	—	Gastrointestinal Stromal Tumor	1	Observed	clinicaltrials	graph →
→ studied in	NCT07585266Phase 3 · recruiting A Study to Investigate Velzatinib Compared With Imatinib in Adult Participants With Previously Untreated Metastatic and/or Unresectable Gastrointestinal Stromal Tumors (StrateGIST Frontline) · condition mapped ALIAS · 1,966 trials mapped (518 active)	—	—	Gastrointestinal Stromal Tumor	1	Observed	clinicaltrials	graph →
→ studied in	NCT04145518Phase 4 · completed Mechanistic Characterization of Uterine Pain · condition mapped ONTOLOGY_EXACT · 1,966 trials mapped (518 active)	—	—	Leiomyoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT04616560Phase 2 · recruiting Trastuzumab Deruxtecan (DS-8201a) for the Treatment of Recurrent or Refractory Osteosarcoma, Wilms Tumor, and Desmoplastic Small Round Cell Tumor · condition mapped ONTOLOGY_EXACT · 1,966 trials mapped (518 active)	—	—	Desmoplastic Small Round Cell Tumor	1	Observed	clinicaltrials	graph →
→ studied in	NCT07837271active not recruiting Development and External Validation of a Prognostic Model for DFS After Curative Resection of Duodenal GIST · condition mapped ONTOLOGY_EXACT · 1,966 trials mapped (518 active)	—	—	Gastrointestinal Stromal Tumor	1	Observed	clinicaltrials	graph →